A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Recruiting
The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: NMCP, Portsmouth, Virginia
Conditions: Crohn Disease, Colitis, Ulcerative
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Recruiting
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC characterized on the basis of epidermal growth factor receptor (EGFR) and Programmed-cell death Ligand (PD-L)1 status, in the Phase 2 (expansion).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Virginia Cancer Specialists, Fairfax, Virginia +6 locations
Conditions: Carcinoma, Non-Small-Cell Lung
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
Recruiting
Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the cells of the body. This causes muscle weakness and other symptoms. Pompe disease can happen at any age, but in late-onset Pompe disease, symptoms generally start from 12 months old onwards. The stand... Read More
Gender:
All
Ages:
Between 16 years and 69 years
Trial Updated:
03/22/2024
Locations: Lysosomal and Rare Diseases Research and Treatment Center, Inc., Fairfax, Virginia +5 locations
Conditions: Pompe Disease (Late-onset)
Tracking a Tactile Signal Along the Nervous System
Recruiting
Quantify the flow of a tactile signal from the stimulus at the finger at the peripheral nervous system (PNS), to the central nervous system (CNS), and to cognitive perception at the brain in young adults (Aim 1) and individuals with and without stroke (Aim 2).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: Virginia Tech, Roanoke, Virginia
Conditions: Stroke, Tactile Perception
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Recruiting
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Virginia Cancer Specialist, Fairfax, Virginia
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
Recruiting
The primary objectives of Part 1 of this study are to: Assess the safety and tolerability of the combination of BGB-3245 and panitumumab in participants with advanced or metastatic colorectal cancer (CRC) with a known mutation status and tumor harboring an oncogenic mutation of v-Raf murine sarcoma viral oncogene homolog B; B-RAF proto-oncogene, serine/threonine kinase (BRAF), Kirsten rat sarcoma viral oncogene homolog (KRAS), or neuroblastoma RAS viral oncogene homolog (NRAS) with documented d... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia
Conditions: Colorectal Cancer, Pancreatic Ductal Cancer, Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
iSIPsmarter: A Pilot RCT to Evaluate a Web-based Behavioral Intervention to Reduce Sugary Beverages Among Black Adults
Recruiting
The proposed pilot randomized controlled trial (RCT) will enroll 24 Black adults. The overall goal is to examine the preliminary efficacy of iSIPsmarter in a 2 group [iSIPsmarter vs. static Patient Education (PE) website] by 4 assessment (Pre, 3-, 6- and 18-month follow-up) design. The generated pilot data will allow us to better understand efficacy and engagement outcomes among Black participants. We anticipate trends that iSIPsmarter will be more efficacious at reducing SSB consumption than a... Read More
Gender:
All
Ages:
Between 18 years and 110 years
Trial Updated:
03/19/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Diet Habit, Sugar-Sweetened Beverages
Adaptive Biobehavioral Control (ABC) in a Closed-Loop System
Recruiting
This study is intended to test a Web-based Information Tool (WIT) software providing additional information regarding time in range, GMI, hypo- and hyperglycemia risks, variability tracker, daily glycemic profiles, and potential changes of insulin pump parameters, to users of a commercially available Closed-Loop Control (CLC) System (Control-IQ Technology).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/19/2024
Locations: University of Virginia Center for Diabetes Technology, Charlottesville, Virginia
Conditions: Type 1 Diabetes
Ultra-processed Food Consumption, Gut Microbiota, and Glucose Homeostasis
Recruiting
Advancing age is associated with gut dysbiosis, low-grade chronic inflammation, progressive insulin resistance, and increased risk of type 2 diabetes (T2D). Prediabetes is present in 45-50% of middle-aged/older adults, and declines in glucose tolerance are evident in the third or fourth decade of life. Thus, there is an urgent need to identify new approaches for the prevention of type 2 diabetes among middle-aged adults. Observational research has linked intake of ultra-processed foods (UPF), wh... Read More
Gender:
All
Ages:
Between 40 years and 65 years
Trial Updated:
03/19/2024
Locations: Virginia Tech, Blacksburg, Virginia
Conditions: Insulin Sensitivity, 24-hour Glucose Control
Comparison of Two Salpingectomy Techniques for Sterilization at the Time of Cesarean Delivery
Recruiting
One in three women of reproductive age utilize tubal sterilization for contraception, and sterilization is often requested at time of cesarean delivery. Complete salpingectomy for the purpose of permanent sterilization at the time of cesarean birth is increasingly being performed worldwide. A preferred complete salpingectomy technique for the purpose of sterilization at the time of cesarean delivery has not emerged in current practice. The objective is to compare short-term clinical outcomes an... Read More
Gender:
Female
Ages:
21 years and above
Trial Updated:
03/19/2024
Locations: Inova Fairfax Medical campus, Falls Church, Virginia
Conditions: Permanent Sterilization, Pregnancy Related
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
Recruiting
Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment to this sub-study per inclusion and exclusion criteria.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Centra Health, Inc.dba Stroobants Cardiovascular Center, Lynchburg, Virginia +1 locations
Conditions: Paroxysmal Atrial Fibrillation
Colchicine in Acutely Decompensated HFREF
Recruiting
This is a double blind, placebo-controlled pilot trial randomizing patients admitted to the hospital with acutely decompensated heart failure (ADHF) and inflammation to receive either colchicine or matching placebo. Upon enrollment, patients will be randomized 1:1 to receive either the experimental drug (Colchicine) or matching placebo. The regimen in the active arm will consist of 14 days of Colchicine 0.6 mg bid followed by 76±14 days of Colchicine 0.6 mg once per day. Placebo regimen will be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: UVA Health, Charlottesville, Virginia
Conditions: Heart Failure, Decompensated Heart Failure, Heart Failure With Reduced Ejection Fraction